These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT. Arthritis Rheum; 2001 Jun; 45(3):252-7. PubMed ID: 11409666 [Abstract] [Full Text] [Related]
28. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916 [Abstract] [Full Text] [Related]
29. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Söderkvist P, Skogh T. Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480 [Abstract] [Full Text] [Related]
30. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349 [Abstract] [Full Text] [Related]
31. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Kristensen LE, Saxne T, Geborek P. Arthritis Rheum; 2006 Feb; 54(2):600-6. PubMed ID: 16447237 [Abstract] [Full Text] [Related]
33. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M, Portales RG, González-Mari MV, Laffón A, García-Vicuña R. Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260 [No Abstract] [Full Text] [Related]
37. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD. Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191 [Abstract] [Full Text] [Related]
38. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. De Rycke L, Vandooren B, Kruithof E, De Keyser F, Veys EM, Baeten D. Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373 [Abstract] [Full Text] [Related]